KGF-2通过调控HMGB1/TLR4通路缓解干眼症
本研究探讨角质细胞生长因子-2(KGF-2)对干眼症(DED)的保护作用及其通过HMGB1/TLR4通路的机制。体外建立高渗人角膜上皮细胞和脂多糖刺激的RAW 264.7细胞模型,体内用东莨菪碱和智能环境系统建立DED小鼠模型。KGF-2治疗显著增加泪液分泌、改善荧光素染色评分并降低炎症因子水平,RNA测序提示其通过调控HMGB1/TLR4通路发挥作用。
要点
- KGF-2治疗显著增加DED小鼠泪液分泌并改善荧光素染色评分。
- KGF-2在体内外模型中均有效降低炎症因子水平。
- KGF-2通过抑制HMGB1上调及核转位调控HMGB1/TLR4通路。
核心结论
- KGF-2在体内外DED模型中通过调控HMGB1/TLR4通路发挥保护作用。
- 这些发现提示KGF-2可能作为DED的治疗剂,需进一步临床研究。
研究设计与样本
- 体外建立高渗人角膜上皮细胞(HCECs)和脂多糖刺激的RAW 264.7细胞模型。
- 使用东莨菪碱和智能环境系统建立DED小鼠模型。
- 采用Western blotting和RT-qPCR检测炎症因子,RNA测序鉴定关键因子,并通过体内外敲低验证。
主要发现
- KGF-2治疗显著缓解DED小鼠症状,表现为泪液分泌增加和荧光素染色评分改善。
- KGF-2在体外和体内模型中均有效降低炎症因子水平。
- Bulk RNA-seq分析提示KGF-2通过调控HMGB1/TLR4通路发挥作用。
- KGF-2抑制DED模型中HMGB1的上调和核转位,从而抑制HMGB1/TLR4通路相关炎症因子水平。
- 在HCECs中敲低HMGB1以及在DED小鼠中给予甘草酸(glycyrrhizin)治疗表现出与KGF-2相似的治疗效果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出这些发现提示KGF-2可能作为DED治疗剂,需进一步临床研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to investigate the protective effects of keratinocyte growth factor-2 (KGF-2) in dry eye disease (DED) and elucidate its mechanism of action through the regulation of the HMGB1/TLR4 pathway. METHODS: Two in vitro models were established by stimulating hyperosmolar human corneal epithelial cells (HCECs) and RAW 264.7 cells with lipopolysaccharide. A DED mice model was established using scopolamine and an intelligently controlled environmental system. After KGF-2 treatment, the symptoms of the DED mice were assessed. The changes in inflammatory factors were measured using Western blotting and quantitative reverse-transcription polymerase chain reaction (RT-qPCR). RNA sequencing (RNA-seq) was used to identify the key factors involved in KGF-2 treatment, followed by validation through in vivo and in vitro knockdown of the relevant factors. RESULTS: KGF-2 treatment significantly relieved DED in the mice model through increased tear secretion, and improved fluorescein staining scores. In addition, the levels of inflammatory factors were effectively lowered in both in vitro and in vivo models. Bulk RNA-seq analysis suggested that KGF-2 exerts its effects by regulating the HMGB1/TLR4 pathway. Furthermore, KGF-2 treatment inhibited the upregulation and nuclear translocation of HMGB1 in the DED model, thereby suppressing the levels of inflammatory factors associated with the HMGB1/TLR4 pathway. Knockdown of HMGB1 in HCECs and glycyrrhizin treatment in DED mice exhibited therapeutic effects similar to those of KGF-2. CONCLUSIONS: KGF-2 demonstrated protective effects in both in vivo and in vitro DED models by modulating the HMGB1/TLR4 pathway. These findings suggest its potential as a therapeutic agent for DED, warranting further clinical investigation in this regard.
引用
- Wang Y, Xu Z, Wei L, et al. KGF-2 Alleviates Dry Eye Disease by Regulating the HMGB1/TLR4 Pathway. Invest Ophthalmol Vis Sci. 2025. PMID: 40227178. doi:10.1167/iovs.66.4.28
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。